Tuesday, November 5, 2024

Scientist.com & Evotec Partner to Speed Drug Discovery

Related stories

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Absci Corporation a data-first generative AI drug creation company, and...

GreyNoise Intelligence Discovers Zero-Day Vulnerabilities in Live Streaming Cameras with the Help of AI

GreyNoise Intelligence, the cybersecurity company providing real-time, verifiable threat...

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials

Medidata, a Dassault Systèmes brand and leading provider of...

Blend Appoints Mike Mischel as SVP of AI Consulting

Blend, a leader in data science and AI-powered solutions,...

Patronus AI Launches Industry-First Self-Serve API for AI Evaluation and Guardrails

Patronus AI announced the launch of the Patronus API, the first...
spot_imgspot_img

Scientist.com, the leading research platform for the pharmaceutical industry, has announced a new partnership with Evotec SE, a leading drug discovery and development company. Through this collaboration, Evotec’s comprehensive suite of R&D services, spanning the entire drug discovery and development process, will now be available to registered users on Scientist.com’s award-winning digital marketplace.

“At Evotec, our mission is to deliver high-quality, efficient, and innovative drug discovery services that advance the work of researchers developing novel treatments,” said Dr. Matthias Evers, Chief Business Officer of Evotec. “By partnering with Scientist.com, we can expand our reach and empower more scientists in their efforts to bring new therapies to market.”

Also Read: SyntheticMR Appoints Francois Hebert as North America President

Evotec offers the Scientist.com research community access to an extensive array of proprietary technologies, including cutting-edge in vitro and in vivo pharmacology, high-throughput screening, and a comprehensive suite of next-generation sequencing tools. Through the marketplace, clients can simplify the procurement process and collaborate with Evotec’s expert team to design and implement customized R&D projects. This partnership allows researchers to tap into Evotec’s deep expertise across various therapeutic areas—such as neuroscience, metabolic diseases, oncology, and infectious diseases—significantly accelerating the journey from concept to clinical reality. Evotec’s offering on Scientist.com also includes predictive toxicology and ADME-PK services through Cyprotex – an Evotec Company.

Evotec‘s unwavering commitment to quality and innovation and the breadth of its offerings aligns perfectly with our mission to connect scientists with the tools and expertise they need to more rapidly advance their drug research,” said Kevin Lustig, PhD, Founder and CEO of Scientist.com. “Through Scientist.com, virtually any research experiment in any therapeutic area can now be seamlessly designed, ordered, and executed.”

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img